Symbols

CASI

CASI Pharmaceuticals·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 2

Bearish signal 2

Consensus Rating "Strong Buy"

Significant Revenue Decline

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CASI

Casi Pharmaceuticals, Inc.

A company that developing multi-mechanism oncology drugs

Industry

Biological Technology

Established Date

Listing Date

06/12/1996

Exchange

NASDAQ Stock Exchange

Full-time Employees

233

Fiscal Year Ends

12-31

Website

www.casipharmaceuticals.com

Security Type

Common stock

Office address

1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, 100025, People’s Republic of China

Business

Introduction

Kaixin Yuanda Pharmaceuticals was incorporated in 1991 and is an exempted company incorporated in the Cayman Islands. The Company is a biopharmaceutical company focused on the development and commercialization of innovative therapies and pharmaceutical products in China, the United States and around the world. The company has built a fully integrated, world-class biopharmaceutical company dedicated to the successful development and commercialization of innovative and other therapeutic products. The company's business development strategy is currently focused on acquiring additional targeted drugs and immuno-oncology therapies through licensing, which will expand the hematology/oncology franchise.

Company Financials

EPS

CASI has released its 2024 Q2 earnings. EPS was reported at -0.52, versus the expected -0.63, beating expectations. The chart below visualizes how CASI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CASI has released its 2025 Q3 earnings report, with revenue of 3.08M, reflecting a YoY change of -60.54%, and net profit of -10.88M, showing a YoY change of -29.64%. The Sankey diagram below clearly presents CASI's revenue sources and cost distribution.